Rosiglitazone is a type 2 diabetes drug in the thiazolidinedione class. In 2011, the U.S. Food and Drug Administration determined that rosiglitzone posed a substantial risk for causing premature cardiovascular disease such as heart attacks. The agency greatly restricted prescribers, essentially killing the drug’s sales in the U.S. In November, the FDA took another look at the data and decided the risk was minimal or non-existent.
Dr. Steven Nissen of the Cleveland Clinic is on record as opposing the new change.
A lot of personal injury lawyers will be disappointed in the change unless they’ve already settled their cases out of court.